Latest Options Offer News

Thrive Tribe Technologies (ASX:1TT) is issuing up to 1.5 billion free attaching options to recent placement participants, exercisable at $0.003 and expiring in 2029, potentially raising $4.5 million if fully exercised.

Bounty Oil & Gas NL has issued a prospectus offering over 632 million new options to eligible investors as part of a broader recapitalisation, potentially raising $6.3 million if exercised.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Ovanti Limited is proposing to issue over 520 million free-attaching options to recent placement investors and its lead manager, exercisable at $0.025 and expiring in 2030, pending shareholder approval.

Strategic Elements Limited is raising up to $1 million via a Share Purchase Plan (SPP) at 3.5 cents per share, with attaching options exercisable at 4 cents, to fuel development in Energy Ink™ and Stealth Technologies.

Catalyst Metals has identified a capital-efficient path to increase throughput at its Plutonic Mill by refurbishing a dormant processing circuit, enhancing flexibility for its ambitious plan to double annual gold production to around 200,000 ounces.

Australian Strategic Materials Limited (ASM) shareholders are set to vote on a scheme of arrangement for Energy Fuels Inc. to acquire 100% of ASM shares and options, offering a significant premium and exposure to a vertically integrated rare earth supply chain.

Critical Resources has launched a systematic field exploration program at the Corona Pegmatite Field, aiming to expand its lithium resource pipeline within the Mavis Lake Project in Ontario, Canada.

Acrux Limited has raised $1.6 million through a discounted share placement, attracting strong demand and offering attaching options to investors. The funds will support Phase III trials for female testosterone and a co-development deal with an international partner.

Critical Resources Limited (ASX:CRR) has initiated a pro-rata entitlement offer of Loyalty Options priced at $0.001 each, aiming to raise $319,410 and potentially $2.56 million upon exercise. The offer underscores significant dilution and operational risks amid ongoing exploration and legal challenges.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.